Literature DB >> 23771238

Reduced striatal ecto-nucleotidase activity in schizophrenia patients supports the "adenosine hypothesis".

Elisabet Aliagas1, Izaskun Villar-Menéndez, Jean Sévigny, Mercedes Roca, Miriam Romeu, Isidre Ferrer, Mireia Martín-Satué, Marta Barrachina.   

Abstract

Schizophrenia (SZ) is a major chronic neuropsychiatric disorder characterized by a hyperdopaminergic state. The hypoadenosinergic hypothesis proposes that reduced extracellular adenosine levels contribute to dopamine D2 receptor hyperactivity. ATP, through the action of ecto-nucleotidases, constitutes a main source of extracellular adenosine. In the present study, we examined the activity of ecto-nucleotidases (NTPDases, ecto-5'-nucleotidase, and alkaline phosphatase) in the postmortem putamen of SZ patients (n = 13) compared with aged-matched controls (n = 10). We firstly demonstrated, by means of artificial postmortem delay experiments, that ecto-nucleotidase activity in human brains was stable up to 24 h, indicating the reliability of this tissue for these enzyme determinations. Remarkably, NTPDase-attributable activity (both ATPase and ADPase) was found to be reduced in SZ patients, while ecto-5'-nucleotidase and alkaline phosphatase activity remained unchanged. In the present study, we also describe the localization of these ecto-enzymes in human putamen control samples, showing differential expression in blood vessels, neurons, and glial cells. In conclusion, reduced striatal NTPDase activity may contribute to the pathophysiology of SZ, and it represents a potential mechanism of adenosine signalling impairment in this illness.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23771238      PMCID: PMC3889387          DOI: 10.1007/s11302-013-9370-7

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  50 in total

1.  Active stress kinase p38 enhances and perpetuates abnormal tau phosphorylation and deposition in Pick's disease.

Authors:  Berta Puig; Francesc Vinals; Isidre Ferrer
Journal:  Acta Neuropathol       Date:  2003-12-20       Impact factor: 17.088

Review 2.  Neurobiology of schizophrenia.

Authors:  Christopher A Ross; Russell L Margolis; Sarah A J Reading; Mikhail Pletnikov; Joseph T Coyle
Journal:  Neuron       Date:  2006-10-05       Impact factor: 17.173

3.  Inhibition of human and mouse plasma membrane bound NTPDases by P2 receptor antagonists.

Authors:  Mercedes N Munkonda; Gilles Kauffenstein; Filip Kukulski; Sébastien A Lévesque; Charlène Legendre; Julie Pelletier; Elise G Lavoie; Joanna Lecka; Jean Sévigny
Journal:  Biochem Pharmacol       Date:  2007-07-27       Impact factor: 5.858

Review 4.  Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia.

Authors:  Isidro Ferrer
Journal:  Prog Neurobiol       Date:  2012-03-21       Impact factor: 11.685

5.  Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling.

Authors:  Ikwunga Wonodi; Hirekatur V Gopinath; Judy Liu; Helene Adami; L Elliot Hong; Robert Allen-Emerson; Robert P McMahon; Gunvant K Thaker
Journal:  Psychopharmacology (Berl)       Date:  2011-05-03       Impact factor: 4.530

6.  Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions.

Authors:  S Akhondzadeh; E Shasavand; H Jamilian; O Shabestari; A Kamalipour
Journal:  J Clin Pharm Ther       Date:  2000-04       Impact factor: 2.512

7.  Alkaline phosphatase is increased in both brain and plasma in Alzheimer's disease.

Authors:  Emma R L C Vardy; Katherine A B Kellett; Sarah L Cocklin; Nigel M Hooper
Journal:  Neurodegener Dis       Date:  2011-10-20       Impact factor: 2.977

8.  Assignment of ecto-nucleoside triphosphate diphosphohydrolase-1/cd39 expression to microglia and vasculature of the brain.

Authors:  N Braun; J Sévigny; S C Robson; K Enjyoji; O Guckelberger; K Hammer; F Di Virgilio; H Zimmermann
Journal:  Eur J Neurosci       Date:  2000-12       Impact factor: 3.386

9.  Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer's disease and dementia with Lewy bodies correlates with stage of Alzheimer's-disease-related changes.

Authors:  José Luis Albasanz; Esther Dalfó; Isidro Ferrer; Mairena Martín
Journal:  Neurobiol Dis       Date:  2005-06-08       Impact factor: 5.996

10.  Ecto-nucleotidases distribution in human cyclic and postmenopausic endometrium.

Authors:  Elisabet Aliagas; August Vidal; Benjamín Torrejón-Escribano; Maria del Rosario Taco; Jordi Ponce; Inmaculada Gómez de Aranda; Jean Sévigny; Enric Condom; Mireia Martín-Satué
Journal:  Purinergic Signal       Date:  2012-12-06       Impact factor: 3.765

View more
  9 in total

Review 1.  Comorbidities in Neurology: Is adenosine the common link?

Authors:  Detlev Boison; Eleonora Aronica
Journal:  Neuropharmacology       Date:  2015-05-13       Impact factor: 5.250

Review 2.  Purinergic system in psychiatric diseases.

Authors:  A Cheffer; A R G Castillo; J Corrêa-Velloso; M C B Gonçalves; Y Naaldijk; I C Nascimento; G Burnstock; H Ulrich
Journal:  Mol Psychiatry       Date:  2017-09-26       Impact factor: 15.992

3.  Adenosine Kinase Expression in the Frontal Cortex in Schizophrenia.

Authors:  Cassidy L Moody; Adam J Funk; Emily Devine; Ryan C Devore Homan; Detlev Boison; Robert E McCullumsmith; Sinead M O'Donovan
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

4.  Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophrenia.

Authors:  Marco Matos; Hai-Ying Shen; Elisabete Augusto; Yumei Wang; Catherine J Wei; Yu Tian Wang; Paula Agostinho; Detlev Boison; Rodrigo A Cunha; Jiang-Fan Chen
Journal:  Biol Psychiatry       Date:  2015-02-27       Impact factor: 13.382

5.  Cell-subtype-specific changes in adenosine pathways in schizophrenia.

Authors:  Sinead Marie O'Donovan; Courtney Sullivan; Rachael Koene; Emily Devine; Kathryn Hasselfeld; Cassidy Lynn Moody; Robert Erne McCullumsmith
Journal:  Neuropsychopharmacology       Date:  2018-02-26       Impact factor: 7.853

Review 6.  Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets.

Authors:  Silvia Pasquini; Chiara Contri; Stefania Merighi; Stefania Gessi; Pier Andrea Borea; Katia Varani; Fabrizio Vincenzi
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

Review 7.  Adenosine, Schizophrenia and Cancer: Does the Purinergic System Offer a Pathway to Treatment?

Authors:  Abdul-Rizaq Hamoud; Karen Bach; Ojal Kakrecha; Nicholas Henkel; Xiaojun Wu; Robert E McCullumsmith; Sinead M O'Donovan
Journal:  Int J Mol Sci       Date:  2022-10-05       Impact factor: 6.208

8.  High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors.

Authors:  Elisabet Aliagas; August Vidal; Laura Texidó; Jordi Ponce; Enric Condom; Mireia Martín-Satué
Journal:  Mediators Inflamm       Date:  2014-02-24       Impact factor: 4.711

Review 9.  Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications.

Authors:  Hamideh Zarrinmayeh; Paul R Territo
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.